Can HMA maintenance therapy improve eligibility for HSCT?

During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to Farhad Ravandi, MD Anderson Cancer Center, Houston, US. We asked, Can HMA maintenance therapy improve eligibility for HSCT?

 

Ravandi begins by highlighting the limited maintenance approaches for patients with AML. He continues with the promising results from the QUAZAR AML-001 study evaluating oral azacitidine (CC-486), an oral hypomethylating agent, which can be used for maintenance and to improve eligibility for hematopoietic stem cell transplantation.


Hosted on Acast. See acast.com/privacy for more information.

More from AML Hub

  1. 03:36What were your highlights from ASH 2023?Apr 29, 2024
  2. 09:19What are the challenges associated with CAR T-cell therapy in patients with AML?Apr 25, 2024
  3. 07:27How might the MORPHO trial of gilteritinib impact clinical practice?Apr 08, 2024
  4. 11:49Risk stratification and guidelines in AML managementJan 08, 2024
  5. 06:04How are new fludarabine conditioning combinations impacting transplant outcomes?Apr 22, 2022
  6. 06:08Should pre-transplant MRD be used to guide treatment in AML?Jul 10, 2021
  7. 13:54Should pre-transplant MRD be used to guide treatment in AML?Jun 25, 2021
  8. 05:03Should pre-transplant MRD be used to guide treatment in AML?Jun 23, 2021
  9. 05:22Can HMA maintenance therapy improve eligibility for HSCT?Mar 17, 2021
  10. 16:07ALLG AMLM16: Does sorafenib plus intensive chemotherapy improve outcome in FLT3-ITD AML?Feb 02, 2021